Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity.

Autor: Jaberi-Douraki M; 1DATA Consortium, Manhattan, USA. jaberi@k-state.edu.; Kansas State University Olathe, Olathe, KS, 66061-1304, USA. jaberi@k-state.edu.; Department of Mathematics, Kansas State University, Manhattan, USA. jaberi@k-state.edu., Meyer E; 1DATA Consortium, Manhattan, USA.; Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, USA., Riviere J; 1DATA Consortium, Manhattan, USA.; Kansas State University, Manhattan, USA.; North Carolina State University, Raleigh, USA., Gedara NIM; 1DATA Consortium, Manhattan, USA.; Kansas State University Olathe, Olathe, KS, 66061-1304, USA.; Department of Business Economics, University of Colombo, Colombo, Sri Lanka., Kawakami J; 1DATA Consortium, Manhattan, USA.; Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, USA.; Molecular Biology and Biochemistry, School of Biological and Chemical Sciences, University of Missouri-Kansas City, Kansas City, USA., Wyckoff GJ; 1DATA Consortium, Manhattan, USA.; Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, USA.; Molecular Biology and Biochemistry, School of Biological and Chemical Sciences, University of Missouri-Kansas City, Kansas City, USA., Xu X; 1DATA Consortium, Manhattan, USA.; Kansas State University Olathe, Olathe, KS, 66061-1304, USA.

Publikováno v: Scientific reports [Sci Rep] 2021 Jun 25; Vol. 11 (1), pp. 13349. Date of Electronic Publication: 2021 Jun 25.